ClinicalTrials.gg
CompletedNCT05070390Updated Aug 19, 2026Results posted

A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

A Phase 1 interventional study of Enlicitide Chloride in Moderate Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study evaluated the safety, tolerability and pharmacokinetic (PK) effects of enlicitide chloride in participants with moderate renal impairment (RI) to those of healthy matched control participants. Moderate RI was defined as the estimated glomerular filtration rate (eGFR) ≥30 and \<60milliliter/minute/1.73meters\^2 (ml/min/1.73m\^2). There is no formal hypothesis.

02

Conditions studied

  • Moderate Renal Impairment
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good health based upon medical history, physical examination, vital signs, laboratory safety tests, and (ECG) performed before randomization
  • (BMI) ≥18 kg/m\^2 and ≤40 kg/m\^2
  • Male participants must agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: Refrain from donating sperm, PLUS either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent, or use acceptable per study protocol
  • Female participants must be of non-
  • Moderate RI participants: Baseline estimated (eGFR) ≥30 and \<60 mL/min/1.73 m\^2 based on the Modification of Diet in Renal Disease (MDRD) equation
  • Moderate Renal Impairment (RI) participants: No change in renal status at least 1 month prior to dosing and not currently receiving or has not previously been on hemodialysis
  • Healthy Matched Controls: eGFR ≥80 mL/min/1.73 m\^2 based on the MDRD equation

Exclusion criteria

Exclusion Criteria:

  • Healthy Matched Controls: history of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator
  • History of cancer, with the exception of adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study
  • History of significant multiple and/or severe allergies
  • Positive for surface antigen (HBsAg), antibodies or (HIV)
  • History of major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit
  • Moderate RI participants: Does not agree to follow the smoking restrictions as defined by the study
  • Healthy Matched Controls: History of smoking and/or has used nicotine or nicotine-containing products (eg, nicotine patch and electronic cigarette) within 3 months of screening
  • Received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention with the exception of Corona virus disease (COVID-19) vaccine administration. Study intervention must be given at least 72 hours following or at least 48 hours prior to any COVID-19 vaccination
  • Consumes greater than 3 servings of alcoholic beverages per day
  • Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
  • Regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 months
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Panel A - Moderate Renal Impairment (RI)

    Single dose of enlicitide chloride 10 mg

    Drug: Enlicitide Chloride

  • Experimental
    Panel B - Healthy Controls

    Single dose of enlicitide chloride 10 mg

    Drug: Enlicitide Chloride

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616

    Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-0616. AUC0-inf was defined as the area under the concentration-time curve of MK-0616 from time zero to infinity.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

  2. Area Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of MK-0616.

    Blood samples were collected at pre-specified timepoints to determine the AUC0-last of MK-0616. AUC0-last was defined as the area under the concentration-time curve of MK-0616 from time zero to last measurable concentration.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

  3. Maximum Plasma Concentration (Cmax) of MK-0616

    Blood samples were collected at pre-specified time points to determine the Cmax of MK-0616. Cmax was defined as the maximum concentration of MK-0616 reached.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

  4. Time to Maximum Plasma Concentration (Tmax) of MK-0616

    Blood samples were collected at pre-specified timepoints to determine the Tmax of MK-0616. Tmax was defined as time to the maximum concentration of MK-0616 reached.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

  5. Apparent Terminal Half-life (t1/2) of MK-0616

    Blood samples were collected at pre-specified timepoints to determine the t1/2 of MK-0616. t1/2 was defined as the time required to divide the MK-0616 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-0616.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

  6. Apparent Clearance (CL/F) of MK-0616

    Blood samples were collected at pre-specified timepoints to determine the CL/F of MK-0616. CL/F was the apparent total clearance of MK-0616 in plasma over time, assessed as the rate at which MK-0616 was removed from the plasma.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

  7. Apparent Volume of Distribution (Vz/F) of MK-0616

    Blood samples were collected at pre-specified timepoints to determine the Vz/F of MK-0616. Vz/F was the apparent volume of distribution of MK-0616 between the plasma and the rest of the body, after dose, assessed as the total volume of MK-0616 that would need to be uniformly distributed to achieve the desired plasma drug concentration.

    Time frame: Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose

Secondary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.

    Time frame: Up to approximately 14 days

  2. Number of Participants Who Discontinued From the Study Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported.

    Time frame: Up to approximately 14 days

  3. Amount Recovered in Urine From 0 to 24 Hours (Ae0-24) of MK-0616

    Urine samples were collected at pre-specified time points to determine the AE0-24 of MK-0616. Ae0-24 was defined as the amount of MK-0616 recovered in urine from time 0-24 hours.

    Time frame: Predose and at 0, 4, 8, 12 and 24 hours postdose

  4. Fraction of Dose Recovered in Urine (Fe) of MK-0616

    Urine samples were collected at pre-specified time points to determine the Fe of MK-0616. Fe was defined as the fraction of dose of MK-0616 recovered in urine.

    Time frame: Predose and at 0, 4, 8, 12, 24, 36 and 48 hours postdose

  5. Renal Clearance (CLr) of MK-0616

    Urine samples were collected at pre-specified time points to determine the CLr of MK-0616. was defined as the time it takes for the MK-0616 to be completely removed by the kidneys.

    Time frame: Predose and 4, 8, 12, 24, 36, and 48 hours postdose

  6. Percent Change From Baseline in Free Proprotein Convertase Subtilisin Kexin 9 (PCSK9)

    Urine samples were collected at pre-specified time points (baseline and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 and 336 hours postdose) to evaluate the reduction in free PCSK9 from baseline to up to 336 hours postdose after administration of MK-0616. The percent change from baseline in free PCSK9 was reported.

    Time frame: Baseline (Predose) and up to 336 hours post dose

07

Results

Posted Sep 26, 2024

Participant flow

Of 24 participants screened for inclusion, 18 participants were allocated to receive MK-0616 single dose 10-mg. All participants received at least one dose of study intervention.

Participant flow — Overall Study
MilestonePanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Started108
Completed108
Not completed00

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616

Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-0616. AUC0-inf was defined as the area under the concentration-time curve of MK-0616 from time zero to infinity.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Geometric mean · hour*nmol/Liter
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616
hour*nmol/LiterPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616453 (211 to 972)369 (211 to 646)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Geometric mean ratio (gmr): 1.23 · 90% CI 0.62 to 2.44GMR and 90% confidence interval (CI) were estimated using a linear mixed effects model and referencing a t-distribution.
PrimaryArea Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of MK-0616.

Blood samples were collected at pre-specified timepoints to determine the AUC0-last of MK-0616. AUC0-last was defined as the area under the concentration-time curve of MK-0616 from time zero to last measurable concentration.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Geometric mean · hour*nmol/Liter
Area Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of MK-0616.
hour*nmol/LiterPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Area Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of MK-0616.312 (120 to 815)192 (64.1 to 574)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 1.63 · 90% CI 0.55 to 4.83GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
PrimaryMaximum Plasma Concentration (Cmax) of MK-0616

Blood samples were collected at pre-specified time points to determine the Cmax of MK-0616. Cmax was defined as the maximum concentration of MK-0616 reached.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Geometric mean · nmol/Liter
Maximum Plasma Concentration (Cmax) of MK-0616
nmol/LiterPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Maximum Plasma Concentration (Cmax) of MK-06165.80 (2.98 to 11.3)4.00 (1.97 to 8.13)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 1.45 · 90% CI 0.70 to 2.99GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
PrimaryTime to Maximum Plasma Concentration (Tmax) of MK-0616

Blood samples were collected at pre-specified timepoints to determine the Tmax of MK-0616. Tmax was defined as time to the maximum concentration of MK-0616 reached.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Median · Hour
Time to Maximum Plasma Concentration (Tmax) of MK-0616
HourPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Time to Maximum Plasma Concentration (Tmax) of MK-06162.00 (1.00 to 24.00)4.66 (1.50 to 24.02)
PrimaryApparent Terminal Half-life (t1/2) of MK-0616

Blood samples were collected at pre-specified timepoints to determine the t1/2 of MK-0616. t1/2 was defined as the time required to divide the MK-0616 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-0616.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Geometric mean · Hour
Apparent Terminal Half-life (t1/2) of MK-0616
HourPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Apparent Terminal Half-life (t1/2) of MK-061655.1 ± 44.148.8 ± 32.0
PrimaryApparent Clearance (CL/F) of MK-0616

Blood samples were collected at pre-specified timepoints to determine the CL/F of MK-0616. CL/F was the apparent total clearance of MK-0616 in plasma over time, assessed as the rate at which MK-0616 was removed from the plasma.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Geometric mean · Liter/hour
Apparent Clearance (CL/F) of MK-0616
Liter/hourPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Apparent Clearance (CL/F) of MK-061614.2 (6.63 to 30.6)17.5 (9.99 to 30.5)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 0.82 · 90% CI 0.41 to 1.62GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
PrimaryApparent Volume of Distribution (Vz/F) of MK-0616

Blood samples were collected at pre-specified timepoints to determine the Vz/F of MK-0616. Vz/F was the apparent volume of distribution of MK-0616 between the plasma and the rest of the body, after dose, assessed as the total volume of MK-0616 that would need to be uniformly distributed to achieve the desired plasma drug concentration.

Time frame:
Predose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours postdose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of MK-0616
LiterPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Apparent Volume of Distribution (Vz/F) of MK-06161130 (675 to 1900)1230 (972 to 1550)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 0.92 · 90% CI 0.60 to 1.42GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.

Time frame:
Up to approximately 14 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Number of Participants Who Experienced an Adverse Event (AE)32
SecondaryNumber of Participants Who Discontinued From the Study Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported.

Time frame:
Up to approximately 14 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From the Study Due to an AE
ParticipantsPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Number of Participants Who Discontinued From the Study Due to an AE00
SecondaryAmount Recovered in Urine From 0 to 24 Hours (Ae0-24) of MK-0616

Urine samples were collected at pre-specified time points to determine the AE0-24 of MK-0616. Ae0-24 was defined as the amount of MK-0616 recovered in urine from time 0-24 hours.

Time frame:
Predose and at 0, 4, 8, 12 and 24 hours postdose
Reported as:
Geometric mean · Miligram
Amount Recovered in Urine From 0 to 24 Hours (Ae0-24) of MK-0616
MiligramPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Amount Recovered in Urine From 0 to 24 Hours (Ae0-24) of MK-06160.0116 (0.00288 to 0.0467)0.0141 (0.00485 to 0.0409)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 0.82 · 90% CI 0.22 to 3.10GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
SecondaryFraction of Dose Recovered in Urine (Fe) of MK-0616

Urine samples were collected at pre-specified time points to determine the Fe of MK-0616. Fe was defined as the fraction of dose of MK-0616 recovered in urine.

Time frame:
Predose and at 0, 4, 8, 12, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · Percent
Fraction of Dose Recovered in Urine (Fe) of MK-0616
PercentPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Fraction of Dose Recovered in Urine (Fe) of MK-06160.116 (0.0288 to 0.467)0.141 (0.0485 to 0.409)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 0.82 · 90% CI 0.22 to 3.10GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
SecondaryRenal Clearance (CLr) of MK-0616

Urine samples were collected at pre-specified time points to determine the CLr of MK-0616. was defined as the time it takes for the MK-0616 to be completely removed by the kidneys.

Time frame:
Predose and 4, 8, 12, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · Liter/hour
Renal Clearance (CLr) of MK-0616
Liter/hourPanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Renal Clearance (CLr) of MK-06160.0573 (0.0157 to 0.209)0.152 (0.0781 to 0.294)
Statistical analysis
  • Panel A - Moderate Renal Impairment (RI) vs Panel B - Healthy Controls · Gmr: 0.38 · 90% CI 0.13 to 1.13GMR and 90% CI were estimated using a linear mixed effects model and referencing a t-distribution.
SecondaryPercent Change From Baseline in Free Proprotein Convertase Subtilisin Kexin 9 (PCSK9)

Urine samples were collected at pre-specified time points (baseline and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 and 336 hours postdose) to evaluate the reduction in free PCSK9 from baseline to up to 336 hours postdose after administration of MK-0616. The percent change from baseline in free PCSK9 was reported.

Time frame:
Baseline (Predose) and up to 336 hours post dose
Reported as:
Geometric mean · Percent Change
Percent Change From Baseline in Free Proprotein Convertase Subtilisin Kexin 9 (PCSK9)
Percent ChangePanel A - Moderate Renal Impairment (RI)Panel B - Healthy Controls
Change from baseline to 1 hour postdose-80.5 (-83.6 to -36.3)-66.6 (-73.4 to -10.2)
Change from baseline to 1.5 hours postdose-90.9 (-97.7 to -66.2)-88.6 (-98.3 to -54.5)
Change from baseline to 2 hours postdose-90.8 (-96.5 to -68.9)-87.1 (-96.8 to -54.9)
Change from baseline to 3 hours postdose-89.7 (-96.1 to -67.1)-86.0 (-95.0 to -60.7)
Change from baseline to 5 hours postdose-89.6 (-94.8 to -73.5)-83.6 (-97.0 to -51.6)
Change from baseline to 8 hours postdose-84.9 (-91.6 to -64.3)-78.5 (-97.8 to -35.1)
Change from baseline to 12 hours postdose-71.8 (-80.4 to -43.5)-60.8 (-93.4 to 9.55)
Change from baseline to 24 hours postdose-67.2 (-75.2 to -43.8)-27.9 (-47.3 to 6.46)
Change from baseline to 36 hours postdose-54.9 (-64.6 to -30.9)1.38 (-26.4 to 47.2)
Change from baseline to 48 hours postdose-44.9 (-56.6 to -15.3)5.11 (-10.2 to 26.2)
Change from baseline to 336 hours postdose5.00 (-9.22 to 27.2)7.50 (-4.78 to 21.2)

Adverse events

Collected over Up to approximately 16 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A - Moderate RI0/10 (0%)0/10 (0%)3/10 (30%)
Panel B - Healthy Controls0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventPanel A - Moderate RIPanel B - Healthy Controls
PalpitationsCardiac disorders0/101/8
DiarrhoeaGastrointestinal disorders0/101/8
FatigueGeneral disorders0/101/8
HeadacheNervous system disorders0/101/8
Axillary painGeneral disorders1/100/8
HypokalaemiaMetabolism and nutrition disorders1/100/8
Muscle spasmsMusculoskeletal and connective tissue disorders1/100/8
DizzinessNervous system disorders1/100/8

Baseline characteristics

All allocated participants.

Age, Continuous
Age, Continuous(Years)Panel A - Moderate Renal Impairment (RI)Panel B - Healthy ControlsTotal
Mean66.5 ± 5.660.4 ± 5.063.8 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Panel A - Moderate Renal Impairment (RI)Panel B - Healthy ControlsTotal
Female538
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A - Moderate Renal Impairment (RI)Panel B - Healthy ControlsTotal
Hispanic or Latino145
Not Hispanic or Latino9413
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A - Moderate Renal Impairment (RI)Panel B - Healthy ControlsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American044
White10414
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Velocity Clinical Research, Hallandale Beach ( Site 0002)
    Hallandale, Florida 33009, United States
  • Alliance for Multispecialty Research, LLC ( Site 0001)
    Knoxville, Tennessee 37920, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in May 2023, 17 months.

Results were first posted in Sep 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2021
First posted
Oct 7, 2021
StartActual
Nov 16, 2021
Primary completionActual
May 3, 2023
CompletionActual
May 3, 2023
Results first posted
Sep 26, 2024
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05070390
Responsible party
Sponsor
First posted
Oct 7, 2021
Start date
Nov 16, 2021
Primary completion
May 3, 2023
Completion
May 3, 2023
Results posted
Sep 26, 2024
Last update
Aug 19, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide chloride

Start the discussion